The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 260 participants.

Also called NCT07120828

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 260 participants (enrolled count) (from the registry)
Sponsor
Erbil Polytechnic University (from the registry)
Registry
  • NCT NCT07120828
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Iraq (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07120828. Randomized; no masking; primary purpose treatment. Start 2025-07-15 (actual); primary completion 2025-08-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
Acronym
CYP8B1-SGLT2-T
Condition
Obese Diabetics
Condition
Obese Patients (BMI ≥ 30 kg/m²)
Intervention (Drug)
Empagliflozin (oral)
Intervention (Drug)
Dapagliflozin (DAPA)
Intervention (Drug)
Metfomin
Lead sponsor
Erbil Polytechnic University (class: other)
Collaborator
Kurdistan Higher Council of Medical Specialties (class: other)

Record details

Record id
cardio:ct-nct07120828
Content hash
ba48a2de53c50cd48bc8d384131434b75b52a10d59daf47a47a7bcf0f6715345